Paradigm Capital Management Inc’s Ocular Therapeutix OCUL Stock Holding History

Paradigm Capital Management Inc’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-400,000	Closed	-$3.42M	–	133
2024 Q4	$3.42M	Hold	400,000	–	–	0.16%	63
2024 Q3	$3.48M	Buy	400,000 +100,000	+33%	+$824K	0.15%	65
2024 Q2	$2.05M	Buy	300,000 +160,000	+114%	+$988K	0.09%	81
2024 Q1	$1.27M	Sell	140,000 -20,000	-13%	-$142K	0.06%	94
2023 Q4	$714K	Buy	160,000 +80,000	+100%	+$237K	0.04%	106
2023 Q3	$251K	Buy	80,000 +40,000	+100%	+$164K	0.01%	131
2023 Q2	$206K	Hold	40,000	–	–	0.01%	134
2023 Q1	$211K	Hold	40,000	–	–	0.01%	133
2022 Q4	$112K	Hold	40,000	–	–	0.01%	142
2022 Q3	$166K	Hold	40,000	–	–	0.01%	140
2022 Q2	$161K	Hold	40,000	–	–	0.01%	145
2022 Q1	$198K	Buy	+40,000	New	+$222K	0.01%	150

Other funds holding OCUL

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Paradigm Capital Management Inc's OCUL Position: Q1 2025 in Review

Paradigm Capital Management Inc sold out of Ocular Therapeutix (OCUL) in Q1 2025, closing a stake of 400,000 shares — an estimated $3.42M sold.

Paradigm Capital Management Inc first reported a position in OCUL in Q1 2022 and held it in 12 quarters. The position peaked at $3.48M in Q3 2024. 196 funds tracked by Wall St. Rank hold OCUL as of Q1 2025.

Paradigm Capital Management Inc reported no remaining Ocular Therapeutix position as of Q1 2025 after selling out during the quarter.
Paradigm Capital Management Inc sold 400,000 Ocular Therapeutix shares in Q1 2025, an estimated $3.42M.
Paradigm Capital Management Inc first reported a position in Ocular Therapeutix in Q1 2022 and held it in 12 quarters.
Paradigm Capital Management Inc's Ocular Therapeutix position peaked at $3.48M in Q3 2024.
196 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2025.

Based on Paradigm Capital Management Inc's 13F filing for Q1 2025, filed 15 May 2025.